CMS Pilot Program for Hemp Products in Medicare Expands Patient Care Options
The Centers for Medicare & Medicaid Services (CMS) recently unveiled a pilot initiative through its Innovation Center, focusing on integrating hemp-derived products into care for Model Participants. Beginning April 1, 2026, the Substance Access Beneficiary Engagement Incentive (BEI) permits healthcare providers in eligible CMS models to offer specific hemp products to Medicare beneficiaries. These products, which are legal under federal guidelines, can be provided up to a value of $500 per beneficiary per year, subject to necessary approvals and comprehensive oversight.
The Substance Access BEI aims to boost patient engagement by allowing providers, at their financial discretion, to supply eligible hemp products to designated beneficiaries. Providers must follow a stringent CMS-approved implementation plan, which includes detailed reporting and rigorous compliance obligations.
Permissible hemp products under this initiative are limited to those compliant with federal legality, containing no more than 0.3% delta-9 THC, and adhering to state and local regulations. Providers must ensure these products meet high quality and safety standards, originate from farms approved by the 2018 Farm Bill, and are subject to third-party testing for potency and contaminants.
Eligibility to access these products is exclusive to Medicare recipients linked with an approved Model Participant. Physicians within these models must assess the appropriateness of these products through documented decision-making with beneficiaries, focusing on evaluating benefits, risks, and potential impacts on existing medications.
Key Considerations for Participation
Organizations evaluating participation in the Substance Access BEI should analyze regulatory obligations and potential risks. While this program expands CMS's operational scope, it also introduces substantial compliance and reporting requirements that must be navigated carefully.
Recently, a legal challenge emerged against the BEI project, with advocacy groups questioning the program's adherence to statutory procedures. The plaintiffs claim the program bypasses legislative processes prescribed by the Administrative Procedures Act. Although a motion for an emergency injunction was initially denied by the court, a future hearing on further motions is anticipated.
Industry professionals will be closely monitoring the ongoing legal proceedings and potential expansion of the program to other CMS models, which could influence future CMS policy directions. For additional insights, stakeholders are encouraged to consult with legal and healthcare advisory teams.